Orpington, UK, 18 July 2014 – Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography (‘OCT’) technology, today announces that leading experts in the use of optical technology in dermatology will be presenting the benefits of multi-beam OCT at the 24th Annual Education Week for Practical Dermatology and Venereology, known as Fortbildungswoche, in Munich, Germany, 19-25 July 2014.
The conference session on ‘Evidence for OCT diagnostics’ will take place at 12:15-13:15, Forum 9, on Friday 25th July.
The presentations include:
• Optical coherence tomography scientific fundamentals and applications, Dr. Martina Ulrich
• Optical coherence tomography for basal cell carcinoma, Prof. Dr. Uwe Reinhold
• Optical coherence tomography (OCT) for Onychomycosis – improving diagnosis and key to a targeted therapy, Prof Dr. Gerald Messer
The Company will also be exhibiting at the congress.
Fortbildungswoche is an annual congress for dermatology and venereology industry experts to further progression in their field through education, training and shared experiences in practical dermatology and venereology. Further information and details on the congress can be accessed through the Fortbildungswoche website: http://www.fortbildungswoche.de.
For further information
Michelson Diagnostics
Tel: +44 (0)20 8308 1695
Jon Holmes, Chief Executive Officer
FTI Consulting
Tel: +44 (0)20 3727 1000
Simon Conway / Mo Noonan / Victoria Foster Mitchell
About Michelson Diagnostics and the VivoSight System Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam Optical Coherence Tomography (‘OCT’), that uses an advanced laser scanner to ‘see’ into tissue with unprecedented image resolution and quality of image. Multi-beam OCT has many potential clinical applications, but we are currently focusing on dermatology.
Our vision is for our VivoSight OCT system to become the standard of care for the non-invasive diagnosis and monitoring of certain diseases and conditions that affect cutaneous and epithelial linings of the body. We currently generate revenues from our first commercial application of VivoSight, which is in the diagnosis of non-melanoma skin cancer (NMSC).
VivoSight has regulatory clearance in Europe, USA and Australia, for use by trained clinicians in their assessment of the patient’s medical condition. We have launched VivoSight in Germany where the VivoSight scan is reimbursed for patients with private healthcare insurance.
The Company, based in Orpington, Kent, was founded in 2006 and has 18 employees. It has sales offices in Germany and USA. It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors. For more information about Michael Diagnostics, see www.michelsondiagnostics.com.
Help employers find you! Check out all the jobs and post your resume.
